ID   SNU-308
AC   CVCL_5048
SY   SNU308; NCI-SNU-308
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN10988081
DR   CCLE; SNU308_BILIARY_TRACT
DR   Cell_Model_Passport; SIDM00161
DR   ChEMBL-Cells; CHEMBL3307456
DR   ChEMBL-Targets; CHEMBL614932
DR   Cosmic; 738869
DR   Cosmic; 2674056
DR   DepMap; ACH-000141
DR   GEO; GSM887620
DR   GEO; GSM888704
DR   IARC_TP53; 28334
DR   KCLB; 00308
DR   LiGeA; CCLE_685
DR   PharmacoDB; SNU308_1454_2019
DR   Wikidata; Q54955169
RX   CelloPub=CLPUB00275;
RX   PubMed=12107841;
RX   PubMed=19956504;
RX   PubMed=22460905;
RX   PubMed=27231123;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: Seoul National University (SNU) cell line collection.
CC   Doubling time: 48 hours (PubMed=12107841).
CC   Sequence variation: Homozygous for TP53 p.Val217Gly (c.650T>G) (CCLE).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.26%; Native American=0%; East Asian, North=62.71%; East Asian, South=35.2%; South Asian=0%; European, North=0%; European, South=1.83% (PubMed=30894373).
ST   Source(s): KCLB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8
ST   D3S1358: 16
ST   D5S818: 9
ST   D7S820: 7,12
ST   FGA: 25,26
ST   TH01: 8
ST   TPOX: 8
ST   vWA: 16
DI   NCIt; C3844; Gallbladder carcinoma
DI   ORDO; Orphanet_56044; Carcinoma of gallbladder and extrahepatic biliary tract
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 19
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   PubMed=12107841; DOI=10.1038/sj.bjc.6600440;
RA   Ku J.-L., Yoon K.-A., Kim I.-J., Kim W.-H., Jang J.-Y., Suh K.-S.,
RA   Kim S.-W., Park Y.-H., Hwang J.-H., Yoon Y.-B., Park J.-G.;
RT   "Establishment and characterisation of six human biliary tract cancer
RT   cell lines.";
RL   Br. J. Cancer 87:187-193(2002).
//
RX   PubMed=19956504; DOI=10.4143/crt.2005.37.1.1;
RA   Ku J.-L., Park J.-G.;
RT   "Biology of SNU cell lines.";
RL   Cancer Res. Treat. 37:1-19(2005).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442;
RA   Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C.,
RA   Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K.,
RA   Greninger P., McDermott U., Garnett M.J., Jenkins R.L.,
RA   Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y.,
RA   Goyal L., Ferrone C.R., Zhu A.X., Joung J.K., Shokat K.M., Benes C.H.,
RA   Bardeesy N.;
RT   "Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity
RT   and SRC dependence in intrahepatic cholangiocarcinoma.";
RL   Cancer Discov. 6:727-739(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//